Gut punch: First Wave's challenger to AbbVie fails phase 2 again

First Wave BioPharma’s bid to challenge AbbVie for a gastrointestinal market has suffered a setback, with the biotech telling investors “it is likely the primary efficacy endpoint was not achieved.”